Despite recent accumulating attention in immunotherapy against NAFLD, the literature remains insufficient to make a conclusive estimation on whether immunotherapy, especially targeting PD-1/PD-L1, may prevent NASH or HCC in patients with HCC. The gene discussed is PDCD1; the disease is metabolic dysfunction-associated steatohepatitis.